Discover why Biogen Inc.'s stock surged 15% in 2025, driven by Skyclarys sales. Explore its strong growth potential and ...

Biogen is showing CEO Michel Vountasos to the door in the aftermath of its Aduhelm debacle. As the company searches for a new leader, one skill set stands out to investors as the most-coveted piece of ...

For years, federal prosecutors have gone after drug companies for allegedly using charity contributions as a way to boost sales. Biogen was among the pharma players to ink a federal settlement, but ...

Biogen is planning to file for FDA approval of its failed Alzheimer’s disease drug aducanumab. The drug flunked a futility analysis in March, but Biogen resurrected it after factoring in data ...

Biogen (BIIB) announced that The Journal of the American Medical Association Neurology has published final results from the ...

Charles Weissmann, molecular biologist, Biogen co-founder and alpha interferon cloner, has died at 94. Here's how he shaped ...

Biogen’s CEO is out. Aduhelm is, essentially, on its last legs. So what’s in? Lecanemab, the monoclonal antibody that the pharma hopes can reset some of the mistakes of the past. Executives detailed a ...

Biogen announced it will buy Human Immunology Biosciences (HI-Bio) in a deal worth up to $1.8 billion Wednesday morning. Per terms of the transaction, Biogen will make an upfront payment of $1.15 ...

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

The downfall of Aduhelm, the first new treatment for Alzheimer’s disease in two decades, is largely the story of a drug company choosing to maximize its potential profits at the expense of patients ...

Biogen’s growth strategy includes M&A deals and the drugmaker is making a big one with the $7.3 billion buyout of Reata Pharmaceuticals, a rare disease company whose main asset is the only ...

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...